JP7470708B2 - 芳香族誘導体、その調製方法および医薬用途 - Google Patents
芳香族誘導体、その調製方法および医薬用途 Download PDFInfo
- Publication number
- JP7470708B2 JP7470708B2 JP2021552591A JP2021552591A JP7470708B2 JP 7470708 B2 JP7470708 B2 JP 7470708B2 JP 2021552591 A JP2021552591 A JP 2021552591A JP 2021552591 A JP2021552591 A JP 2021552591A JP 7470708 B2 JP7470708 B2 JP 7470708B2
- Authority
- JP
- Japan
- Prior art keywords
- foregoing
- pharma
- compound
- tautomer
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/076926 | 2019-03-05 | ||
| PCT/CN2019/076926 WO2020177067A1 (en) | 2019-03-05 | 2019-03-05 | Aromatic derivatives, preparation methods, and medical uses thereof |
| PCT/CN2020/075849 WO2020177534A1 (en) | 2019-03-05 | 2020-02-19 | Aromatic derivatives, preparation methods, and medical uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522890A JP2022522890A (ja) | 2022-04-20 |
| JP2022522890A5 JP2022522890A5 (cg-RX-API-DMAC7.html) | 2023-02-28 |
| JP7470708B2 true JP7470708B2 (ja) | 2024-04-18 |
Family
ID=72337401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552591A Active JP7470708B2 (ja) | 2019-03-05 | 2020-02-19 | 芳香族誘導体、その調製方法および医薬用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11976058B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3935048A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7470708B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210135558A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111902400B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132405A1 (cg-RX-API-DMAC7.html) |
| PH (1) | PH12021552133A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202109522VA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI860334B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2020177067A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12595370B2 (en) | 2018-03-02 | 2026-04-07 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
| US10935695B2 (en) | 2018-03-02 | 2021-03-02 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
| US12595371B2 (en) | 2018-03-02 | 2026-04-07 | Johnson & Johnson Vision Care, Inc. | Contact lens with improved vision break-up time |
| US12674032B2 (en) | 2019-06-28 | 2026-07-07 | Johnson & Johnson Vision Care, Inc. | Polymerizable fused tricyclic compounds as absorbers of UV and visible light |
| US20220194944A1 (en) * | 2020-12-18 | 2022-06-23 | Johnson & Johnson Vision Care, Inc. | Photostable mimics of macular pigment |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| JP2015523383A (ja) | 2012-07-11 | 2015-08-13 | ブループリント メディシンズ コーポレイション | 線維芽細胞成長因子受容体の阻害剤 |
| WO2016064960A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| JP2016519673A (ja) | 2013-03-15 | 2016-07-07 | セルジーン アビロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびそれらの使用 |
| CN107286130A (zh) | 2016-04-13 | 2017-10-24 | 成都融科博海科技有限公司 | 一种激酶选择性抑制剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012271357A1 (en) | 2011-06-16 | 2013-05-02 | Ionis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
| JP6084292B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Fgfr阻害剤耐性癌の治療薬 |
| SG11201602069WA (en) | 2013-10-18 | 2016-04-28 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| CN105683188B (zh) | 2013-10-25 | 2018-02-09 | 诺华股份有限公司 | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 |
| JP6655559B2 (ja) | 2014-06-24 | 2020-02-26 | コベストロ、ドイチュラント、アクチエンゲゼルシャフトCovestro Deutschland Ag | ジフェニルメタン系ジアミンおよびポリアミンの製造方法 |
| EP3029864B1 (en) | 2014-12-01 | 2020-11-18 | Harman Becker Automotive Systems GmbH | Fast representation of station information in a fm receiver using a single tuner |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) * | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN105906630B (zh) | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物 |
| WO2016164703A1 (en) | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
| RU2747260C2 (ru) * | 2016-12-19 | 2021-04-29 | Аббиско Тхерапеутицс Цо., Лтд. | Ингибитор рфрф4, способ его получения и его фармацевтическое применение |
| CN110997637B (zh) * | 2017-09-05 | 2022-09-27 | 保仕健生物科技(上海)有限公司 | 芳香类衍生物、其制备方法及其在医药上的应用 |
| CN109224235B (zh) | 2018-10-23 | 2020-05-19 | 孙喜家 | 一种双腔管 |
| CN109331654A (zh) | 2018-10-26 | 2019-02-15 | 高邮高和光电器材有限公司 | 一种有机废气光催化氧化装置 |
-
2019
- 2019-03-05 WO PCT/CN2019/076926 patent/WO2020177067A1/en not_active Ceased
-
2020
- 2020-02-19 EP EP20767365.8A patent/EP3935048A4/en not_active Withdrawn
- 2020-02-19 WO PCT/CN2020/075849 patent/WO2020177534A1/en not_active Ceased
- 2020-02-19 CN CN202080000743.2A patent/CN111902400B/zh active Active
- 2020-02-19 KR KR1020217031713A patent/KR20210135558A/ko not_active Ceased
- 2020-02-19 CA CA3132405A patent/CA3132405A1/en active Pending
- 2020-02-19 JP JP2021552591A patent/JP7470708B2/ja active Active
- 2020-02-19 US US17/436,476 patent/US11976058B2/en active Active
- 2020-02-19 PH PH1/2021/552133A patent/PH12021552133A1/en unknown
- 2020-02-19 SG SG11202109522VA patent/SG11202109522VA/en unknown
- 2020-03-05 TW TW109107205A patent/TWI860334B/zh active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015523383A (ja) | 2012-07-11 | 2015-08-13 | ブループリント メディシンズ コーポレイション | 線維芽細胞成長因子受容体の阻害剤 |
| JP2016519673A (ja) | 2013-03-15 | 2016-07-07 | セルジーン アビロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびそれらの使用 |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| WO2016064960A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| CN107286130A (zh) | 2016-04-13 | 2017-10-24 | 成都融科博海科技有限公司 | 一种激酶选择性抑制剂 |
Non-Patent Citations (1)
| Title |
|---|
| Shraga, Amit et al.,Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor,Cell Chemical Biology,2019年,26(1),98-108 |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202109522VA (en) | 2021-09-29 |
| WO2020177067A1 (en) | 2020-09-10 |
| US20220169634A1 (en) | 2022-06-02 |
| CN111902400A (zh) | 2020-11-06 |
| US11976058B2 (en) | 2024-05-07 |
| WO2020177534A1 (en) | 2020-09-10 |
| PH12021552133A1 (en) | 2022-08-22 |
| CA3132405A1 (en) | 2020-09-10 |
| EP3935048A1 (en) | 2022-01-12 |
| EP3935048A4 (en) | 2022-11-09 |
| KR20210135558A (ko) | 2021-11-15 |
| TWI860334B (zh) | 2024-11-01 |
| JP2022522890A (ja) | 2022-04-20 |
| TW202100514A (zh) | 2021-01-01 |
| CN111902400B (zh) | 2024-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12083124B2 (en) | Bicyclic heterocycles as FGFR inhibitors | |
| WO2024218686A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| WO2024213979A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| EP4551296A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| US11976058B2 (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| US20250034173A1 (en) | Pyrido[4,3-d]pyrimidine compounds | |
| WO2025101776A1 (en) | Heterocycles and uses thereof | |
| US12263171B2 (en) | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
| JP2025100453A (ja) | ピリド[4,3-d]ピリミジン化合物 | |
| JP2018507214A (ja) | Fgfr4阻害剤としての二環式複素環 | |
| US12428420B2 (en) | Tricyclic heterocycles as FGFR inhibitors | |
| US20230399327A1 (en) | High activity hpk1 kinase inhibitor | |
| US20240083898A1 (en) | Tricyclic triazolo compounds as dgk inhibitors | |
| US12600723B2 (en) | Tetracyclic compounds as DGK inhibitors | |
| WO2024003773A1 (en) | 2,7-naphthyridine compounds as mastl inhibitors | |
| US11377444B2 (en) | Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors | |
| WO2020198067A1 (en) | Pkm2 modulators and methods for their use | |
| HK40040054A (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| HK40040054B (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| US20250163059A1 (en) | Heterocyclic kinase inhibitors | |
| TW202545531A (zh) | 氮—喹唑啉化合物之使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230217 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240220 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240321 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240408 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7470708 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |